RVTY
Neutral signalScored 2026-09-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Revvity, Inc.
- Nom
- Revvity, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NYSE
- Capitalisation
- $17.7B
- Employés
- 11,000
- PDG
- Prahlad R. Singh
- Site web
- https://www.revvity.com
- Marché
- ABIOCRLDHRMLABMTD
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 85 titres (~9306 USD)
- Insiders
- Gonzales Anita
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,281,439
Avg sell (VWAP, 90d window) $141.67 vs last close $151.53 (+7.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,281,439 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-07-20
- Liquidity
- Liquid $341,346,562/day · 20d vol
- Last synced
-
2026-10-19 22:38:55
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-01 | Gonzales Anita | Sell · S · 10b5-1 | 84 | $155.48 | $13,060 | Form 4 |
| 2026-09-21 | Krakowiak Maxwell | Sell · S · 10b5-1 | 1,631 | $144.53 | $235,728 | Form 4 |
| 2026-09-16 | Vohra Tajinder S | Sell · S · 10b5-1 | 7,330 | $140.88 | $1,032,650 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-09 | Gilbert Cisneros | Sale (Partial) | $15,001 - $50,000 |
| 2026-09-04 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2026-09-03 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2026-05-04 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
| 2026-05-01 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-12 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-13 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-07-23 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-17 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-11 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-05-28 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-02-28 | April McClain Delaney | Sale | $15,001 - $50,000 |
| 2025-02-25 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-07-19 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Sale | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
RVTY presents a weak overall profile with both financial health (45) and catalyst (35) scores below conviction thresholds: deteriorating margins, elevated debt-to-EBITDA, and a debt service coverage ratio below 1.0…
The first sentence of the analysis written for RVTY on 2026-09-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. 2 purchase disclosures year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 1.68 · operating margin 12%
Suggested stop 137.27, nearest stored support minus 0.5 ATR(9.4% under the last close). Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 53.1% | 48.0% | 48.1% | 53.2% | 59.6% | |
| Ebit Margin | 12.6% | 15.0% | 10.2% | 22.8% | 34.1% | |
| Ebitda Margin | 26.8% | 30.5% | 25.9% | 35.7% | 42.2% | |
| Operating Profit Margin | 12.5% | 14.9% | 14.5% | 23.6% | 35.0% | |
| Pretax Profit Margin | 9.4% | 11.5% | 6.7% | 19.7% | 31.4% | |
| Continuous Operations Profit Margin | 8.5% | 10.3% | 6.5% | 15.5% | 23.2% | |
| Net Profit Margin | 8.5% | 10.7% | -4.3% | 17.2% | 24.6% | |
| Bottom Line Profit Margin | 8.5% | 10.7% | -4.3% | 17.2% | 24.6% | |
| Current Ratio | 1.682 | 3.598 | 2.069 | 2.129 | 2.011 | |
| Quick Ratio | 1.397 | 3.035 | 1.774 | 1.867 | 1.660 | |
| Solvency Ratio | 0.132 | 0.153 | 0.055 | 0.148 | 0.160 | |
| Cash Ratio | 0.691 | 1.781 | 0.630 | 0.294 | 0.497 | |
| Price To Earnings Ratio | 46.688 | 46.187 | -115.148 | 31.079 | 24.764 | |
| Price To Earnings Growth Ratio | -3.410 | -0.131 | 0.951 | -0.699 | 1.016 | |
| Forward Price To Earnings Growth Ratio | -3.410 | -0.131 | 0.951 | -0.699 | 1.016 | |
| Price To Earnings Diluted Ratio | 46.688 | 46.187 | -115.148 | 31.145 | 24.872 | |
| Price To Earnings Diluted Growth Ratio | -3.410 | -0.131 | 0.951 | -0.703 | 1.017 | |
| Price To Book Ratio | 1.516 | 1.782 | 1.731 | 2.396 | 3.271 | |
| Price To Sales Ratio | 3.849 | 4.960 | 4.956 | 5.341 | 6.102 | |
| Price To Free Cash Flow Ratio | 21.631 | 25.227 | 1,376.352 | 29.771 | 17.631 | |
| Price To Operating Cash Flow Ratio | 18.898 | 21.748 | 149.349 | 26.021 | 16.556 | |
| Debt To Assets Ratio | 0.289 | 0.268 | 0.300 | 0.325 | 0.344 | |
| Debt To Equity Ratio | 0.485 | 0.434 | 0.516 | 0.622 | 0.723 | |
| Debt To Capital Ratio | 0.327 | 0.303 | 0.341 | 0.384 | 0.420 | |
| Long Term Debt To Capital Ratio | 0.277 | 0.291 | 0.288 | 0.347 | 0.411 | |
| Financial Leverage Ratio | 1.678 | 1.616 | 1.723 | 1.914 | 2.101 | |
| Working Capital Turnover Ratio | 2.193 | 1.697 | 1.670 | 2.229 | 4.221 | |
| Operating Cash Flow Ratio | 0.437 | 0.962 | 0.063 | 0.440 | 1.162 | |
| Operating Cash Flow Sales Ratio | 0.204 | 0.228 | 0.033 | 0.205 | 0.369 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.874 | 0.862 | 0.109 | 0.874 | 0.939 | |
| Debt Service Coverage Ratio | 1.087 | 8.363 | 0.865 | 1.815 | 12.250 | |
| Interest Coverage Ratio | 3.869 | 4.264 | 4.043 | 7.514 | 13.121 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.988 | 2,596.277 | 0.126 | 1.444 | 332.724 | |
| Operating Cash Flow Coverage Ratio | 0.165 | 0.189 | 0.022 | 0.148 | 0.273 | |
| Capital Expenditure Coverage Ratio | 7.913 | 7.251 | 1.122 | 7.939 | 16.400 | |
| Dividend Paid And Capex Coverage Ratio | 5.472 | 5.188 | 0.785 | 5.619 | 11.916 | |
| Dividend Payout Ratio | 0.136 | 0.116 | -0.295 | 0.062 | 0.034 | |
| Enterprise Value Multiple | 17.747 | 18.835 | 23.521 | 18.457 | 17.261 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 53.1% | ▲5.1% | ▲0.7% |
| Ebit Margin | 12.6% | ▼-2.4% | ▼-6.3% |
| Ebitda Margin | 26.8% | ▼-3.7% | ▼-5.4% |
| Operating Profit Margin | 12.5% | ▼-2.4% | ▼-7.6% |
| Pretax Profit Margin | 9.4% | ▼-2.1% | ▼-6.3% |
| Continuous Operations Profit Margin | 8.5% | ▼-1.8% | ▼-4.3% |
| Net Profit Margin | 8.5% | ▼-2.3% | ▼-2.9% |
| Bottom Line Profit Margin | 8.5% | ▼-2.3% | ▼-2.9% |
| Current Ratio | 1.682 | ▼-1.915 | ▼-0.615 |
| Quick Ratio | 1.397 | ▼-1.637 | ▼-0.549 |
| Solvency Ratio | 0.132 | ▼-0.022 | ▲0.002 |
| Cash Ratio | 0.691 | ▼-1.090 | ▼-0.088 |
| Price To Earnings Ratio | 46.688 | ▲0.501 | ▲39.974 |
| Price To Earnings Growth Ratio | -3.410 | ▼-3.279 | ▼-2.955 |
| Forward Price To Earnings Growth Ratio | -3.410 | ▼-3.279 | ▼-2.955 |
| Price To Earnings Diluted Ratio | 46.688 | ▲0.501 | ▲39.939 |
| Price To Earnings Diluted Growth Ratio | -3.410 | ▼-3.279 | ▼-2.954 |
| Price To Book Ratio | 1.516 | ▼-0.266 | ▼-0.623 |
| Price To Sales Ratio | 3.849 | ▼-1.110 | ▼-1.192 |
| Price To Free Cash Flow Ratio | 21.631 | ▼-3.595 | ▼-272.491 |
| Price To Operating Cash Flow Ratio | 18.898 | ▼-2.850 | ▼-27.617 |
| Debt To Assets Ratio | 0.289 | ▲0.021 | ▼-0.016 |
| Debt To Equity Ratio | 0.485 | ▲0.051 | ▼-0.071 |
| Debt To Capital Ratio | 0.327 | ▲0.024 | ▼-0.028 |
| Long Term Debt To Capital Ratio | 0.277 | ▼-0.014 | ▼-0.046 |
| Financial Leverage Ratio | 1.678 | ▲0.062 | ▼-0.128 |
| Working Capital Turnover Ratio | 2.193 | ▲0.496 | ▼-0.209 |
| Operating Cash Flow Ratio | 0.437 | ▼-0.525 | ▼-0.176 |
| Operating Cash Flow Sales Ratio | 0.204 | ▼-0.024 | ▼-0.004 |
| Free Cash Flow Operating Cash Flow Ratio | 0.874 | ▲0.011 | ▲0.142 |
| Debt Service Coverage Ratio | 1.087 | ▼-7.276 | ▼-3.789 |
| Interest Coverage Ratio | 3.869 | ▼-0.395 | ▼-2.693 |
| Short Term Operating Cash Flow Coverage Ratio | 0.988 | ▼-2595.289 | ▼-585.324 |
| Operating Cash Flow Coverage Ratio | 0.166 | ▼-0.024 | ▲0.006 |
| Capital Expenditure Coverage Ratio | 7.913 | ▲0.662 | ▼-0.212 |
| Dividend Paid And Capex Coverage Ratio | 5.472 | ▲0.284 | ▼-0.324 |
| Dividend Payout Ratio | 0.136 | ▲0.019 | ▲0.125 |
| Enterprise Value Multiple | 17.747 | ▼-1.088 | ▼-1.417 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $10.99B | $13.66B | $13.63B | $17.69B | $23.36B | |
| Enterprise value | $13.59B | $15.83B | $16.78B | $21.83B | $27.91B | |
| EV / Sales | 4.76x | 5.75x | 6.10x | 6.59x | 7.29x | |
| EV / Op. cash flow | 23.36x | 25.19x | 183.88x | 32.11x | 19.79x | |
| EV / Free cash flow | 26.74x | 29.22x | 1694.62x | 36.74x | 21.07x | |
| EV / EBITDA | 17.75x | 18.84x | 23.52x | 18.46x | 17.26x | |
| Net debt / EBITDA | 3.39x | 2.57x | 4.42x | 3.50x | 2.82x | |
| Current ratio | 1.68x | 3.60x | 2.07x | 2.13x | 2.01x | |
| Income quality | 2.41x | 2.22x | 0.51x | 1.33x | 1.59x | |
| Graham number | $55 | $58 | — | $77 | $106 | |
| Graham net-net | -$29 | -$24 | -$27 | -$45 | -$56 | |
| Tax burden | 90.1% | 93.6% | -64.7% | 87.3% | 78.4% | |
| Interest burden | 74.4% | 76.7% | 64.9% | 86.2% | 92.2% | |
| Working capital | $908.5M | $1.70B | $1.55B | $1.74B | $1.23B | |
| Invested capital | $10.51B | $11.45B | $11.77B | $12.27B | $12.33B | |
| Return on assets | 2.0% | 2.4% | -0.9% | 4.0% | 6.3% | |
| Operating ROA | 2.9% | 3.2% | 2.9% | 5.4% | 11.7% | |
| Return on tangible assets | 7.5% | 9.0% | -3.0% | 13.3% | 20.7% | |
| Return on equity | 3.3% | 3.9% | -1.5% | 7.7% | 13.2% | |
| Return on invested capital | 2.8% | 3.1% | 3.0% | 4.7% | 7.2% | |
| Return on capital employed | 3.3% | 3.5% | 3.3% | 6.2% | 9.7% | |
| Earnings yield | 2.2% | 2.2% | -0.9% | 3.2% | 4.0% | |
| Free cash flow yield | 4.6% | 4.0% | 0.1% | 3.4% | 5.7% | |
| Capex / Op. cash flow | 12.6% | 13.8% | 89.1% | 12.6% | 6.1% | |
| Capex / Depreciation | 18.1% | 20.3% | 18.8% | 20.1% | 27.6% | |
| Capex / Sales | 2.6% | 3.1% | 3.0% | 2.6% | 2.2% | |
| SG&A / Sales | 33.1% | 26.0% | 25.7% | 22.9% | 19.4% | |
| R&D / Sales | 7.6% | 7.1% | 7.9% | 6.7% | 5.2% | |
| Stock comp / Sales | 0.8% | 1.4% | 1.5% | 1.6% | 0.8% | |
| Intangibles / Total assets | 73.6% | 73.5% | 70.4% | 69.8% | 69.7% | |
| Days sales outstanding | 95d | 84d | 84d | 68d | 68d | |
| Days payables outstanding | 51d | 43d | 52d | 64d | 77d | |
| Operating cycle | 199d | 177d | 193d | 163d | 168d | |
| Cash conversion cycle | 148d | 135d | 141d | 99d | 91d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-14 How to Invest in AI Drug Discovery .Danaher (DHR), one of the world''s largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.
- 2026-10-13 Revvity to Present at Upcoming Investor Conferences WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 2026 8:00 a.m. GMT – Prahlad Singh, president and chief executive officer 9th Annual Evercore Healthcare Conference Wednesday, December 2, 2026 9:10 a.m. ET – Prahlad Singh Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be.
- 2026-10-06 Revvity to Host Investor Day WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.Presentations from members of Revvity''s senior management team will provide updates on the Company''s key business initiatives, operational achievements and financial outlook.To register for the Investor Day webcast, visit here. A replay of the webcast and all presentations will be available on the Events page of the Revvity Investor Relations webs.
- 2026-10-02 Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock? Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-10-02 Revvity to Hold Earnings Call on November 3, 2026 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section o.
- 2026-10-01 Revvity (NYSE:RVTY) Hits New 12-Month High – Here’s Why Revvity Inc. (NYSE: RVTY - Get Free Report) shares reached a new 52-week high on Thursday. The stock traded as high as $158.28 and last traded at $153.6540, with a volume of 4432400 shares trading hands. The stock had previously closed at $152.77. Analyst Ratings Changes A number of analysts have issued reports on RVTY shares.
- 2026-09-29 Here''s Why You Should Retain Revvity Stock in Your Portfolio for Now RVTY''s diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.
- 2026-09-25 RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.
- 2026-09-24 Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear. A critical public health challenge, T1D is often only identified after significant beta-cell damage has occurred, presenting first as a life-threatening diabetic k.
- 2026-09-24 Reviewing Codexis (NASDAQ:CDXS) & Revvity (NYSE:RVTY) Revvity (NYSE: RVTY - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Institutional and Insider Ownership 86.7% of Revvity shares are held